HEALTH● LOWOct 7 · Oct 7, 2026, 3:12 AM
Enliven, FDA agree on phase 3 trial design for relcobatinib for chronic myeloid leukemia
Seeking Alpha Tech · global
Enliven and the FDA have reached an agreement on the design for a Phase 3 trial of relcobatinib, a treatment for chronic myeloid leukemia, marking a step forward in drug development.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH5m agoClimate change is putting Europe’s brain health at riskEuroNews [en]HEALTH14m agoOlympic Qualifier: Eguavoen speaks on Ajibade’s injury, hails Okpe after big winPremium TimesHEALTH29m agoMother's journey with sick child highlights Somalia's malnutrition emergencyAfricanews [en]HEALTH30m agoProgress against HIV stalls in South Africa, research showsThe Telegraph